Physician profile
Whitnee C Brown
NPI 1699149948
$4,907.21
in general payments reported to CMS, 2019-2025
25 companies · $245 in 2025
The $245 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $985 · 2022: $839 · 2023: $956 · 2024: $1,882 · 2025: $245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,483 · Consulting Fee: $600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,482.94 |
| Consulting Fee | $600.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,017.34 | 2021-2025 | |
| Myriad Genetic Laboratories, INC. | $600.00 | 2024 | Genesight |
| Neurocrine Biosciences, INC. | $538.00 | 2022-2024 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $512.63 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $313.67 | 2022-2024 | Caplyta |
| Astrazeneca Pharmaceuticals Lp | $229.98 | 2021-2022 | |
| Novo Nordisk INC | $214.46 | 2021-2023 | Wegovy |
| Teva Pharmaceuticals USA, INC. | $163.65 | 2022-2024 | Austedo Xr, Uzedy |
| Takeda Pharmaceuticals U.S.A., INC. | $142.12 | 2021-2024 | Trintellix |
| Alnylam Pharmaceuticals INC. | $140.07 | 2021-2024 | Amvuttra |
| Janssen Pharmaceuticals, INC | $135.46 | 2022-2025 | Spravato |
| Lundbeck LLC | $123.99 | 2022-2024 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $121.34 | 2024 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.22 | 2021 | |
| Supernus Pharmaceuticals, INC. | $113.70 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $98.56 | 2023 | |
| Alkermes, INC. | $95.74 | 2024 | Aristada, Lybalvi |
| Pharmacyclics LLC, An Abbvie Company | $68.12 | 2023 | Imbruvica, Epkinly |
| Corium, LLC | $46.31 | 2023-2024 | Azstarys |
| Sanofi Pasteur INC. | $21.80 | 2025 | |
| Tris Pharma INC | $21.09 | 2024 | Dyanavel Xr |
| Acadia Pharmaceuticals INC | $20.75 | 2024 | Nuplazid |
| Noven Therapeutics, LLC | $19.71 | 2024 | Xelstrym, Secuado |
| Neos Therapeutics, Lp | $14.51 | 2021 | |
| Impel Pharmaceuticals INC. | $13.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Whitnee Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.